Positive Reports, page-25

Actually this discussion raises another interesting issue in relation to the available patient pool.
The average life expectancy for Rett’s syndrome sufferers is about 24 years, but with good care some will make it to 40 or 50. Now imagine if, with early intervention and a fairly normal growth development, that average was suddenly pushed out to 40 or 50. Over time, your patient pool would start to grow quite a bit because the natural attrition factor had been reduced significantly. Now in 40 or 50 years the treatment would have become generic and the cost come down massively, if it was even still relevant, due to new therapies being developed, but in the medium term, this could offset dropout rates quite a bit.